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Genome-wide mRNA and miRNA expression profiling
revealmultiple regulatory networks in colorectal cancer
R Vishnubalaji1, R Hamam1, M-H Abdulla2, MAV Mohammed2, M Kassem1,3,4, O Al-Obeed2, A Aldahmash1,3 and NM Alajez*,1
Despite recent advances in cancer management, colorectal cancer (CRC) remains the third most common cancer and a major
health-care problem worldwide. MicroRNAs have recently emerged as key regulators of cancer development and progression by
targeting multiple cancer-related genes; however, such regulatory networks are not well characterized in CRC. Thus, the aim of this
study was to perform global messenger RNA (mRNA) and microRNA expression profiling in the same CRC samples and adjacent
normal tissues and to identify potential miRNA-mRNA regulatory networks. Our data revealed 1273 significantly upregulated and
1902 downregulated genes in CRC. Pathway analysis revealed significant enrichment in cell cycle, integrated cancer, Wnt
(wingless-type MMTV integration site family member), matrix metalloproteinase, and TGF-β pathways in CRC. Pharmacological
inhibition of Wnt (using XAV939 or IWP-2) or TGF-β (using SB-431542) pathways led to dose- and time-dependent inhibition of CRC
cell growth. Similarly, our data revealed up- (42) and downregulated (61) microRNAs in the same matched samples. Using target
prediction and bioinformatics, ~ 77% of the upregulated genes were predicted to be targeted by microRNAs found to be
downregulated in CRC. We subsequently focused on EZH2 (enhancer of zeste homolog 2 ), which was found to be regulated by
hsa-miR-26a-5p and several members of the let-7 (lethal-7) family in CRC. Significant inverse correlation between EZH2 and
hsa-miR-26a-5p (R2= 0.56, P= 0.0001) and hsa-let-7b-5p (R2= 0.19, P= 0.02) expression was observed in the same samples,
corroborating the belief of EZH2 being a bona fide target for these two miRNAs in CRC. Pharmacological inhibition of EZH2 led to
significant reduction in trimethylated histone H3 on lysine 27 (H3K27) methylation, marked reduction in cell proliferation, and
migration in vitro. Concordantly, small interfering RNA-mediated knockdown of EZH2 led to similar effects on CRC cell growth
in vitro. Therefore, our data have revealed several hundred potential miRNA-mRNA regulatory networks in CRC and suggest
targeting relevant networks as potential therapeutic strategy for CRC.
Cell Death and Disease (2015) 6, e1614; doi:10.1038/cddis.2014.556; published online 22 January 2015
Colorectal cancer (CRC) is among the most prevalent types of
cancers causing high mortality rates around the world. CRC is
the third most common type of cancer (1.23 million, 9.7% up to
2010) in both genders (males (10%) and females (9.4%)), with
the highest rates in New Zealand, Australia, and Western
Europe.1 CRC has been reported as the fourth most common
malignancy (male 7.6%, female 8.6%), particularly in Central
and Eastern Europewhere it has been reported for the highest
mortality rate in both genders.1 In eastern Asia, countries such
as Japan, China, South Korea, and Singapore experienced a
two- to four fold increase in CRC incidence in the past few
decades.2 Similar trends have been observed in Saudi
Arabia.3 In the Kingdom of Saudi Arabia, CRC is the most
common cancer form among men and the second most
common cancer amongwomen, where 66.1% of CRC incident
cases were reported in males and 33.9% in women.4
The 5-year overall survival was reported to be 63.3% for
patients with localized disease, 50.2% for those with regional
disease, and 14.7% for patients with distant metastases.4 In
developing countries, the 5-year survival rates for CRC range
from 28 to 42%.5
The conventional chemotherapy for CRC involves the use of
highly toxic drugs with many undesirable side effects,6,7
underscoring the need to identify novel biomarkers for early
diagnosis and for better disease stratification and treatment
choices. Recently, microRNAs (miRNAs) have emerged as
having a key role in cancer development, progression,
and resistance to chemotherapy.8,9,10 miRNAs are noncoding
small RNAs (20–22 nucleotides), which possess posttran-
scriptional regulatory functions in diverse biological processes
such as proliferation, apoptosis, cell cycle regulation, stem
cell maintenance, differentiation, development, metabolism,
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and aging.8,11,12,13,14,15 A variety of methods have been used
ranging from miRNA microarrays to global miRNA expression
profiling with deep sequencing to determine the expression
pattern of miRNAs in cancer tissues.16,17 Abnormal expres-
sion of miRNAs has been associated with a large number of
human cancers. In CRC, a number of studies have reported
altered miRNA expression pattern, suggesting a plausible role
for the aberrant miRNA expression in CRC biology.17,18 The
natural mechanisms for the dysregulation of miRNAs are still
largely unknown, although gene amplification, genomic loss,
and promoter hypermethylation have been reported as the
potential mechanisms in various cancers.14,19,20 Strategies
based on restoration of downregulated miRNAs or inhibition of
upregulated miRNAs have opened a new area of investigating
the potential therapeutic value in cancer therapy.
Previous studies have examined global messenger RNA
(mRNA) and miRNA expression in CRC;21,22,23 however, only
a few have examined the global miRNA andmRNA expression
profiling in the same CRC tissue and compared with matched
normal tissues.24 Thus, we performed global mRNA and
miRNA expression profiling in 13 CRC specimens and their
matched adjacent normal tissues obtained from Saudi
patients. We identified more than 700 potential miRNA-
mRNA regulatory networks in CRC controlling various key
pathways relevant to CRC development, progression, and
therapy failure.
Results
Gene expression profiling in CRC. Global gene expression
profiling was conducted on 13 colon cancer specimens and
13 adjacent normal tissues. The clinical characteristics of
patients involved in current study are provided in Table 1.
As shown in Figure 1a, hierarchical clustering based on
differentially expressed mRNAs revealed clear separation of
the two groups where the cancer tissues clustered separately
from the normal tissues, except for one branch of the cancer
group representing one cancer sample, which was misclas-
sified to the normal group. Using significance analysis, 1273
up- and 1902 downregulated genes were identified (2.0 FC,
Po0.02; Supplementary Table 1). Pathway analysis on the
upregulated genes using GeneSpring GX revealed significant
enrichment in several pathways related to cell cycle, DNA
damage, matrix metalloproteases, Wnt, and TGF-β signaling
(Figure 1b and Supplementary Table 2). The Wnt and TGF-β
signaling pathways are illustrated in Supplementary Figures 1
and 2. To confirm their relevance to CRC, we used small-
molecule inhibitors to inhibit the Wnt (XAV939 and IWP-2)
or TGF-β (SB-431542) signaling in HT115 cells, which
led to significant reduction in cell viability (Figure 1c).
Selected number of the upregulated (wingless-type MMTV
integration site family member 2 (WNT2), matrix metallopep-
tidase 9 (MMP9), enhancer of zeste homolog 2 (EZH2)) and
downregulated (bone morphogenetic protein 3 (BMP3))
genes from the microarray data were subsequently validated
using quantitative reverse transcription-PCR (qRT-PCR)
(Figure 1d). Small-interfering RNA (siRNA)-mediated knock-
down of FOXM1 (forkhead box protein M1) and FOXQ1
(forkhead box protein Q1) reduced HT115 cell growth in vitro
(Supplementary Figure 3), corroborating a biological
relevance of the identified genes from the microarray in
CRC biology.
miRNA expression profiling in CRC. To identify potential
miRNA-mRNA regulatory networks in CRC, we performed
global miRNA expression profiling on the same 13 cancer
and adjacent normal samples that were used for mRNA
profiling shown in Figure 1. Using significant analysis, we
identified 61 significantly downregulated and 42 significantly
upregulated miRNAs (1.5-fold change, Po0.02; Table 2).
Hierarchical clustering of the differentially expressed miRNAs
in 13 colon cancer specimes and 13 normal tissues is shown
in Figure 2a. The data revealed clear separation of the two
groups. We subsequently focused on the downregulated
miRNAs and their correlation with the upregulated target
genes. Using TargetScan prediction feature in GeneSpring
GX software (Agilent Technologies, Santa Carla, CA, USA),
16 157 genes were predicted to be targeted by the identified
downregulated miRNAs (Supplementary Table 3). Pathway
analysis using the predicted gene targets revealed significant
Table 1 Clinical characteristics for the patients used in the current study
No. Age (years) Sex Site of cancer Adenocarcinoma Histological
grade
Clinical stage TNM classification
1 70 Male Sigmoid Yes G2 Stage III T4 N1 M1
2 47 Male Sigmoid Yes G2 Stage III T3 N1 M1
3 50 Male Colon Yes G2 Stage II T3 N0 M0
4 56 Female Rectum Yes G2 Stage II T3 N0 M0
5 59 Male Colon and rectum Yes G2 Stage III T3 N2 M1
6 72 Male Sigmoid Yes G2 Stage II T3 N0 M0
7 70 Male Rectum Yes G2 Stage III T3 N2 M1
8 68 Female Colon Yes G2 Stage II T4 N0 M0
9 57 Female Rectosigmoid Yes G2 Stage III T3 N2 M1
10 61 Female Sigmoid Yes G2 Stage II T3 N0 M0
11 30 Female Sigmoid Yes G2 Stage III T2 N1 M1
12 57 Male Sigmoid Yes G3 Stage III T3 N1 M1
13 59 Female Sigmoid Yes G2 Stage III T3 N1 M1
Abbreviations: M, presence of distant metastasis; N, degree of spread to regional lymph nodes; T, size or direct extent of the primary tumor
Classification of malignant tumors (TNM)
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Figure 1 Differentially expressed genes in CRC. (a) Hierarchical clustering of 13 CRC and 13 adjacent normal tissue samples based on differentially expressed mRNA levels.
Each column represents a sample and each row represents a transcript. Expression level of each gene in a single sample is depicted according to the color scale. (b) Pie chart
illustrating the distribution of the top 20 pathway designations for the upregulated genes in colon cancer cells. The pie size corresponds to the number of matched entities.
(c) Inhibition of Wnt pathways using XAV 939 and IWP-2 or TGF-β pathway using SB-431542 small-molecule inhibitors led to significant reduction in cell viability in HT115 colon
cancer cells. Data are presented as mean±S.E., n= 24. (d) Expression levels of selected genes (WNT2,MMP9, EZH2, and BMP3) based on the microarray data and validation
of those genes using qRT-PCR (duplicate). **Po0.005; **Po0.0005
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Table 2 Differentially expressed miRNAs between colorectal cancer specimens and normal tissues
Updated systematic name FC C versus N Log FC C
versus N
Regulation C
versus N
miRBase accession no.
Downregulated miRs
hsa-miR-133b −226.08115 −7.820697 Down MIMAT0000770
hsa-miR-378a-5p −110.78563 −6.791627 Down MIMAT0000731
hsa-miR-139-5p − 84.79849 −6.4059668 Down MIMAT0000250
hsa-miR-133a − 84.60821 −6.4027257 Down MIMAT0000427
hsa-miR-145-3p − 74.17002 −6.2127643 Down MIMAT0004601
hsa-miR-1 − 58.168026 −5.8621545 Down MIMAT0000416
hsa-miR-30e-3p − 32.476025 −5.021303 Down MIMAT0000693
hsa-miR-143-5p − 31.099096 −4.958801 Down MIMAT0004599
hsa-miR-29c-5p − 28.070925 −4.8110046 Down MIMAT0004673
hsa-miR-486-5p − 21.722443 −4.4411144 Down MIMAT0002177
hsa-miR-99a-5p − 20.735474 −4.374029 Down MIMAT0000097
hsa-miR-139-3p − 20.527025 −4.3594527 Down MIMAT0004552
hsa-miR-363-3p − 17.026367 −4.089699 Down MIMAT0000707
hsa-miR-490-5p − 16.500505 −4.0444384 Down MIMAT0004764
hsa-miR-129-1-3p − 16.097223 −4.00874 Down MIMAT0004548
hsa-miR-4328 − 15.330928 −3.938373 Down MIMAT0016926
hsa-miR-3675-3p − 14.637202 −3.871568 Down MIMAT0018099
hsa-miR-145-5p − 13.633393 −3.7690728 Down MIMAT0000437
hsa-miR-28-3p − 10.397909 −3.3782215 Down MIMAT0004502
hsa-miR-1267 − 10.369238 −3.374238 Down MIMAT0005921
hsa-miR-3679-3p −9.957987 −3.315854 Down MIMAT0018105
hsa-miR-1227 −9.898095 −3.3071508 Down MIMAT0005580
hsa-miR-99b-5p −8.877857 −3.1502116 Down MIMAT0000689
hsa-miR-4324 −8.527493 −3.0921216 Down MIMAT0016876
hsa-miR-100-5p −8.12212 −3.0218563 Down MIMAT0000098
hsa-miR-143-3p −7.537136 −2.9140165 Down MIMAT0000435
hsa-miR-634 −7.271931 −2.8623385 Down MIMAT0003304
hsa-miR-129-2-3p −6.9524083 −2.7975128 Down MIMAT0004605
hsa-miR-490-3p −6.2970576 −2.6546779 Down MIMAT0002806
hsa-miR-497-5p −5.41665 −2.4374008 Down MIMAT0002820
hsa-miR-28-5p −5.246121 −2.391251 Down MIMAT0000085
hsa-miR-378a-3p −5.230102 −2.3868392 Down MIMAT0000732
hsa-miR-30a-5p −5.11498 −2.3547287 Down MIMAT0000087
hsa-miR-125b-5p −3.6129825 −1.8531903 Down MIMAT0000423
hsa-miR-195-5p −3.1166792 −1.6400096 Down MIMAT0000461
hsa-miR-375 −3.0833967 −1.6245205 Down MIMAT0000728
hsa-miR-125a-5p −2.7951596 −1.4829307 Down MIMAT0000443
hsa-miR-23b-3p −2.5185568 −1.3325973 Down MIMAT0000418
hsa-miR-30c-5p −2.4603393 −1.2988573 Down MIMAT0000244
hsa-miR-548c-5p −2.393883 −1.2593527 Down MIMAT0004806
hsa-miR-150-5p −2.1257915 −1.0880002 Down MIMAT0000451
hsa-miR-140-3p −1.9857309 −0.98967016 Down MIMAT0004597
hsa-miR-27b-3p −1.8863192 −0.91557384 Down MIMAT0000419
hsa-miR-3653 −1.8339884 −0.8749845 Down MIMAT0018073
hsa-miR-320a −1.8225296 −0.86594224 Down MIMAT0000510
hsa-let-7c −1.821517 −0.86514044 Down MIMAT0000064
hsa-miR-26a-5p −1.7855949 −0.8364048 Down MIMAT0000082
hsa-let-7b-5p −1.7462178 −0.80423355 Down MIMAT0000063
hsa-miR-365a-3p −1.7350858 −0.79500705 Down MIMAT0000710
hsa-miR-320e −1.724407 −0.78610027 Down MIMAT0015072
hsa-miR-320d −1.7153007 −0.77846146 Down MIMAT0006764
hsa-miR-320b −1.7146243 −0.7778925 Down MIMAT0005792
hsa-miR-361-5p −1.687753 −0.7551037 Down MIMAT0000703
hsa-miR-30e-5p −1.6607047 −0.73179555 Down MIMAT0000692
hsa-miR-4313 −1.6525247 −0.72467184 Down MIMAT0016865
hsa-miR-320c −1.6258739 −0.7012154 Down MIMAT0005793
hsa-miR-29c-3p −1.6134787 −0.69017446 Down MIMAT0000681
hsa-let-7b-3p −1.6106501 −0.68764305 Down MIMAT0004482
hsa-miR-149-5p −1.5800085 −0.6599323 Down MIMAT0000450
hsa-let-7 g-5p −1.5541947 −0.6361673 Down MIMAT0000414
hsa-miR-423-5p −1.5068012 −0.5914891 Down MIMAT0004748
Upregulated miRs
hsa-miR-135b-5p 348.6332 8.445566 Up MIMAT0000758
hsa-miR-96-5p 133.09624 7.056326 Up MIMAT0000095
hsa-miR-424-5p 85.915306 6.4248433 Up MIMAT0001341
hsa-miR-18a-5p 55.54994 5.7957134 Up MIMAT0000072
hsa-miR-31-5p 37.379402 5.2241716 Up MIMAT0000089
hsa-miR-224-5p 34.20287 5.0960455 Up MIMAT0000281
hsa-miR-1290 31.966501 4.998489 Up MIMAT0005880
hsa-miR-130b-3p 27.430082 4.777687 Up MIMAT0000691
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enrichment for several pathways such as cancer, TGF-β, FAK
(focal adhesion kinase), Wnt, and MAPK (mitogen-activated
protein kinase). Top 20 enriched pathways based on
TargetScan prediction are shown in Figure 2b. We subse-
quently focused on the upregulated genes in CRC speci-
mens, which could potentially be regulated by miRNAs found
to be downregulated in the same specimens. Crossing the list
of predicted gene targets for downregulated miRNAs with the
list of the upregulated genes in CRC revealed 794 upregu-
lated genes, which were predicted to be targeted by down-
regulated miRNAs in CRC (Figure 2c and Supplementary
Table 4). The expression levels of selected number of the
identified miRNAs from the microarray data (hsa-miR-145-5p,
hsa-miR-26a-5p, and hsa-miR-30a-5p) were subsequently
validated using Taqman qRT-PCR (Figure 2d).
Depletion of EZH2/PRC2 complex reduces colon cancer
cell proliferation and cell migration. Among the identified
upregulated genes in our study is EZH2. Elevated expre-
ssion of EZH2 has been observed in different human
cancers,13,25,26,27 which we found to be upregulated in CRC
in the current study as well (Figure 1d and Supplementary
Table 1). To assess the biological ramifications of EZH2
depletion on CRC cancer cells, we treated HT115, HT-29,
and SW620 colon cancer cells with 3-deazaneplanocin A
(DZNep), a small-molecule inhibitor known to target EZH2
protein, and assessed cell viability on days 4 and 8
posttreatment. As shown in Figure 3a, a significant dose-
and time-dependent decrease in colon cancer cell viability
was observed, which was associated with a reduction in
EZH2 protein expression (Figure 3b, left) and a marked
reduction in tri-methylated lysine 27 (H3K27-3me) (Figure 3b,
right). Concordant with these data, HT115 cells treated with
DZNep also exhibited marked reduction in cell migration as
measured using transwell migration assay (Figure 3c). To
identify the molecular pathways regulated by EZH2 in CRC,
HT115 cells were treated with DZNep to induce reduction in
EZH2 and subsequently examined the effects of reduced
EZH2 on global gene expression using microarray analysis
(Figure 3d). Pathway analysis on the differentially expressed
genes revealed multiple enriched pathways including senes-
cence and autophagy, apoptosis, and FAK (Figure 3e and
Supplementary Table 5). The senescence and autophagy
pathway is illustrated in Supplementary Figure 4, with all
matched entities indicated.
EZH2 is regulated by several miRNAs in CRC. Our results
suggest that EZH2 is involved in multiple aspects of
CRC cell biology; therefore, we hypothesized that the
elevated expression of EZH2 in CRC could be attributed
to the downregulation of miRNAs that targets EZH2.
Figure 4a illustrates the map for EZH2 3′-untranslated
region (UTR) and the list of miRNAs predicted to target
EZH2 based on TargetScan prediction. Among the pre-
dicted miRNAs, EZH2 was found to be regulated by six
microRNAs (hsa-miR-26a-5p, hsa-Let-7b-5p, hsa-Let-7c-5p,
Table 2 (Continued )
Updated systematic name FC C versus N Log FC C
versus N
Regulation C
versus N
miRBase accession no.
hsa-miR-532-5p 23.844732 4.5755987 Up MIMAT0002888
hsa-miR-3648 22.774778 4.509365 Up MIMAT0018068
hsa-miR-203 18.44064 4.204817 Up MIMAT0000264
hsa-miR-21-3p 17.213509 4.105469 Up MIMAT0004494
hsa-miR-660-5p 15.831627 3.9847376 Up MIMAT0003338
hsa-miR-182-5p 15.797628 3.981636 Up MIMAT0000259
hsa-miR-95 15.297556 3.9352293 Up MIMAT0000094
hsa-miR-7-5p 12.604156 3.6558275 Up MIMAT0000252
hsa-miR-3127-5p 12.075171 3.5939717 Up MIMAT0014990
hsa-miR-18b-5p 11.8246565 3.5637264 Up MIMAT0001412
hsa-miR-622 10.575571 3.4026637 Up MIMAT0003291
hsa-miR-3156-5p 10.303987 3.3651307 Up MIMAT0015030
hsa-miR-652-3p 9.751009 3.2855515 Up MIMAT0003322
hsa-miR-371a-5p 8.452332 3.0793493 Up MIMAT0004687
hsa-miR-183-5p 7.5481267 2.9161186 Up MIMAT0000261
hsa-miR-491-5p 7.534784 2.913566 Up MIMAT0002807
hsa-miR-3198 6.5412736 2.7095716 Up MIMAT0015083
hsa-miR-19a-3p 4.7948313 2.26148 Up MIMAT0000073
hsa-miR-210 4.494275 2.1680884 Up MIMAT0000267
hsa-miR-1246 4.1132383 2.0402746 Up MIMAT0005898
hsa-miR-21-5p 3.5413451 1.8242974 Up MIMAT0000076
hsa-miR-3647-5p 2.8310268 1.5013254 Up MIMAT0018066
hsa-miR-20a-5p 2.7826865 1.4764783 Up MIMAT0000075
hsa-miR-17-5p 2.56975 1.361628 Up MIMAT0000070
hsa-miR-1274a 2.368945 1.2442446 Up MIMAT0005927
hsa-miR-19b-3p 2.231824 1.1582232 Up MIMAT0000074
hsa-miR-491-3p 2.1232426 1.0862693 Up MIMAT0004765
hsa-miR-663a 2.0279565 1.0200267 Up MIMAT0003326
hsa-miR-20b-5p 1.9541535 0.9665438 Up MIMAT0001413
hsa-miR-106b-5p 1.9268446 0.94624025 Up MIMAT0000680
hsa-miR-3651 1.8909732 0.91912895 Up MIMAT0018071
hsa-miR-642b-3p 1.8161368 0.86087286 Up MIMAT0018444
hsa-miR-221-3p 1.698573 0.76432323 Up MIMAT0000278
hsa-miR-425-5p 1.6854963 0.75317353 Up MIMAT0003393
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Figure 2 miRNA expression profiling in CRC. (a) Hierarchical clustering of 13 colon cancer and 13 normal tissue samples based on miRNA expression levels. Each column
represents a sample and each row represents a transcript. Expression level of each miRNA in a single sample is depicted according to the color scale. (b) Pie chart illustrating the
distribution of the top 20 pathway designations for predicted targets (TargetScan) for the downregulated miRNAs in colon cancer. The pie size corresponds to the number of
matched entities. (c) Venn diagram depicting the overlap between the predicted gene targets for the downregulated miRNAs (based on TargetScan) versus the differentially
upregulated genes in CRC identified in the current study. (d) Expression levels of selected miRNAs (hsa-miR-145-5p, hsa-miR-26a-5p, and hsa-miR-30-5p) based on microarray
data and validation of those miRNAs using Taqman qRT-PCR (duplicate). **Po0.005; ***Po0.0005
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hsa-Let-7e-5p, hsa-Let-7g-5p, and hsa-miR-363-3p), which
were downregulated in CRC (Figure 4b and Table 2). We
subsequently focused on hsa-miR-26a-5p and hsa-let-7b-5p,
as we previously reported those two miRNAs to target EZH2
in nasopharyngeal carcinoma.13 The alignment between
EZH2 3′-UTR and these two miRNAs is shown in Figure 4c
(upper panel). Overexpression of hsa-miR-26a-5p or hsa-let-
7b-5p in HT115 cells led to significant reduction in EZH2
protein levels (Figure 4c, lower panel). Interestingly,
significant inverse relationship between EZH2 and hsa-
miR-26a-5p (R2= 0.56, P=0.0001) and hsa-let-7b-5p
(R2=0.19, P=0.02) expression by microarray was obser-
ved in the 13 CRC and their matched adjacent normal tissue
specimens (Figure 4d), corroborating EZH2 being relevant
biological target for these two miRNAs in CRC. Exogenous
expression of hsa-miR-26a-5p and hsa-let-7b-5p (Figure 4e,
upper panel) led to significant reduction in cell viability, similar
to those seen with EZH2 knockdown (Figure 4e, lower panel).
Figure 3 Inhibition of EZH2 using DZNep mediates significant reduction in cell viability and in vitro migration in colon cancer cells. (a) HT115, HT-29, and SW620 cells were
treated with the indicated dose of DZNep, and cell viability was measured on days 4 and 8 posttreatment using the alamarBlue assay. Data are presented as mean± S.E., n= 8.
(b) DZNep treatment (5 days) led to significant reduction in EZH2 protein expression in HT-29 and SW620 cells. Similarly, DZNep treatment led to substantial reduction in
H3K273me in the colon cancer cells. *Po0.05, n= 2. (c) DZNep treatment led to remarkable reduction in HT115 cell in vitro transwell migration. (d) Hierarchical clustering of
HT115 treated with DZNep (5 μM) compared with controls based on mRNA expression levels. Each column represents one replica. Expression level of each gene in a single
replica is depicted according to the color scale. (e) Pie chart illustrating the distribution of the top 20 pathway designations for the differentially expressed genes in HT115-DZNep
versus control. The pie size corresponds to the number of matched entities
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Figure 4 Regulation of EZH2 by hsa-miR-26a and hsa-let-7 family in CRC. (a) Schematic presentation showing miRNAs predicted to target EZH2 using TargetScan
database. (b) EZH2 is predicted to be regulated by several members of the let-7 family, miR-26a-5p, and miR-363-3p, which were downregulated in colon cancer. (c) Schematic
presentation depicting alignment of Let-7b-5p and miR-26a-5p mature sequence, and the putative binding sites within the 3′-UTR region of the EZH2 mRNA using TargetScan
database. The exact positions of the interaction between EZH2 3′-UTR and both miRNA seed regions are indicated. Immunoblotting for EZH2 protein in HT115 transfected with
the indicated pre-miRs at 48 h posttransfection. GAPDH was used as a loading control. (d) Inverse relationship between EZH2 and hsa-miR-26a-5p and hsa-let-7b-5p expression
in 13 CRC and matched normal tissues. (e) siRNA-mediated knockdown of EZH2 (lower panel) or exogenous expression of hsa-let7-b-5p and hsa-miR-26a-5p (upper panel) led
to significant reduction in cell viability in HT115 colon cancer cell. Data are presented as mean± S.E., n= 12. *Po0.05; **Po0.005; ***Po0.0005
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Discussion
Although a number of previous studies have examined mRNA
and/or miRNA expression in CRC,21,22,23,28,29 only few studies
have examined global mRNA and miRNA expression in the
same clinical samples,24,30 none so far has been conducted in
this geographical region. Therefore, the strength of our
approach is that it enables the identification of deregulated
mRNA-miRNA networks in the same biological specimens.
Our data revealed more than 700 potential miRNA-mRNA
regulatory networks in CRC and thus provide circumstantial
evidence for the involvement of miRNAs in the pathogenesis
of colorectal cancer. In addition, our data provide a compre-
hensive molecular profiling of CRC in Saudi Arabia and the
Middle East.
Several of the deregulatedmRNAs andmiRNAs identified in
the current study have been reported previously, suggesting a
common underlying molecular mechanisms leading to CRC
pathogenesis regardless of ethnicity. For instance, hsa-miR-
-135b, hsa-miR-223, hsa-miR-18a, hsa-miR-17, hsa-miR-31,
and hsa-miR-21 were upregulated in our study, and were also
reported by a previous study.18 Similarly, we found hsa-
miR-375, hsa-miR-195, hsa-miR-378, hsa-miR-143, hsa-miR-
-145, hsa-miR-29c, hsa-miR-1, hsa-miR-30c, hsa-miR-30e,
hsa-miR-26a, hsa-miR-100, and hsa-miR-338-3p to be down-
regulated in CRC in our data, which were also reported to be
downregulated in colon cancer patients from Northern
Europe.18
Our data revealed several additional novel miRNAs, which
have not been reported previously (Table 2), possibly because
of a more comprehensive coverage of miRNAs in the miRNA
microarray chips that cover 1205 human miRNAs and used in
our study. Our gene expression data revealed multiple
deregulated pathways in colon cancer such as cell cycle,
DNA damage response, Wnt signaling, and matrix metallo-
proteases signaling, which is concordant with previous studies
implicating these pathways in CRC.31,32 We found that
pharmacological inhibition of Wnt or TGF-β signaling impaired
colon cancer cell proliferation in vitro (Figure 1c), which
suggests a biological relevance for these pathways in CRC.
Several of the identified pathways in CRC were found to be
among the predicted targets for miRNAs identified in our study,
which suggest a plausible role for the identified miRNAs in the
pathogenesis of CRC. We have chosen EZH2, which is a
member of the polycomb gene (PcG) family, as it has been
implicated in the pathogenesis of a number of other cancer
types.13,25–27 EZH2 is the catalytic subunit of the polycomb
repressive complex 2 (PRC2), which is responsible for
methylation of lysine 27 on histone H3. This epigenetic
modification of H3 is necessary for gene repression through
the PRC2 complex. Our current study suggests that EZH2 has
a role in the pathogenesis of CRC. Pharmacological inhibition
of EZH2 led to significant decrease in H3K27-3me, significant
decrease in cell viability, and migration in CRC cells. In
addition, siRNA-mediated knockdown of EZH2 exhibited
profound effects on colorectal cancer cell growth in vitro.
In silico prediction has identified several potential miRNAs
targeting EZH2 in colon cancer cells, and forced expression of
hsa-miR-26a-5p and hsa-let7b-5p phenocopied the effects of
EZH2 depletion in CRC cells, supporting a role of the two
miRNAs in regulating EZH2 expression in colorectal cancer.
Our data are concordant with our previous publication
implication hsa-miR-26a-5p and hsa-let-7 family in regulating
EZH2 in nasopharyngeal carcinoma.13 Interestingly, we
observed significant inverse relationship between EZH2 and
hsa-miR-26a-5p and hsa-let-7b-5p expression in CRC
(Figure 4d), corroborating the biological relevance of this
regulatory network in this disease.
In our current study, we have validated one regulatory
network for its relevance in CRC cell biology. However, we
provided information regarding several other potential regula-
tory networks (Supplementary Tables 3 and 4) in CRC that
remain to be investigated.
Materials and Methods
Ethics statement. The clinical study and collection of tissue samples were
approved by Institutional Research Ethics Board at the King Saud University
College of Medicine (Riyadh, Riyadh, Saudi Arabia).
Patient and tissue collection. Tissue specimens from 13 fresh-frozen
consecutive sporadic CRCs matched with their adjacent normal mucosa were
obtained from previously untreated patients who underwent surgical resection at the
King Khaled University Hospital (Riyadh, Saudi Arabia). Tumor and their paired
normal mucosa were selected by an experienced pathologist and specimens were
snap frozen in liquid nitrogen and stored at − 80 °C until use. Clinical information of
the patients is provided in Table 1.
Tissue preparation and RNA isolation. Tissues were ground to powder
using a mortar and pestle in the presence of liquid nitrogen. RNA was isolated from
~ 100 to 300 mg of tissue per sample using the Total Tissue RNA Purification Kit
from Norgen-Biotek Corp. (Thorold, ON, Canada). The resulting RNA was quantified
using NanoDrop 2000 (Thermo Scientific, Wilmington, DE, USA) and the RNA
quality and integrity was confirmed using gel electrophoresis.
Gene expression profiling. Total RNA was extracted as described above
using Total RNA Purification Kit (Norgen-Biotek Corp.) according to the
manufacturer’s instructions. One hundred and fifty nanograms of total RNA was
labeled and then hybridized to the Agilent Human SurePrint G3 Human GE 8 × 60 k
v16 microarray chip (Agilent Technologies). All microarray experiments were
conducted at the Microarray Core Facility (Stem Cell Unit, King Saud University
College of Medicine). Normalization and data analyses were conducted using
GeneSpring GX software (Agilent Technologies). Pathway analysis were conducted
using the Single Experiment Pathway analysis feature in GeneSpring 12.0 (Agilent
Technologies) as described before.33,34 Twofold cutoff with Po0.02 was used.
miRNA expression profiling. miRNA expression profiling was conducted
on the same 13 RNA samples used for gene expression profiling. Two hundred
nanograms of the extracted total RNA was used for RNA labeling and hybridization
on to the Agilent Human SurePrint G3 8 × 60k v16 miRNA microarray chip
according to the manufacturer's protocol. Data were subsequently normalized and
analyzed using GeneSpring GX software (Agilent Technologies). A fold-change of
1.5 with Po0.02 was used as cutoff to determine the differentially expressed
miRNA in cancer versus normal tissues. Target prediction was conducted using a
built-in feature in GeneSpring GX based on TargetScan database.
mRNA and miRNA validation by qRT-PCR. Both mRNA and miRNA
expression levels were validated in CRC and normal tissues using qRT-PCR method
using the Applied Biosystem (ABI) Detection system. For mRNA expression
detection, 2 μg of total RNA was reverse transcribed using High Capacity cDNA
Reverse Transcript Kit (Part No: 4368814; ABI) according to the manufacturer’s
protocol. Relative levels of mRNA were determined from cDNA using real-time
PCR (Applied Biosystems StepOnePlus Real-Time PCR Systems). Primer
sequences used in the current study were: WNT2 (F), 5′-GCGCATTTGTGG
ATGCAAAG-3′ and (R), 5′-ACCGCTTTACAGCCTTCCTG-3′; BMP3 (F), 5′-GCAG
CAGCAGAAACTCTTGAAA-3′ and (R), 5′-AGACACTGGACAACTCAGGC-3;
MMP9 (F), 5′-CGGTTTGGAAACGCAGATGG-3′ and (R), 5′-TGGGTGTAGAGTCT
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CTCGCT-3′; and EZH2 (F), 5′-GCGCGGGACGAAGAATAATCAT-3′ and (R),
5′-TACACGCTTCCGCCAACAAACT-3′. For miRNA expression detection, 10 ng
of total RNA was reverse transcribed using TaqMan MicroRNA Reverse
Transcription Kit (Part No: 4366596; ABI), and relative miRNA expression levels
were determined using TaqMan Universal Master Mix II, No UNG (Part No:
4440040), and hsa-miR-26a-5p (Assay ID: 000405), hsa-miR-30a-5p (Assay ID:
000417), and hsa-miR-145-5p (Assay ID: 002278) from ABI. The relative expression
level was calculated using –ΔΔCT. RNU44/RNU48 was used as an endogenous
control for miRNA expression, whereas β-actin was used as an endogenous control
for mRNA expression.
Cell culture. Human colorectal cell lines HT-29, HT115, and SW620 were
purchased from CLS Cell Lines Service GmbH (Eppelheim, Germany). The cell line
was incubated in Dulbecco's modified Eagle's medium supplemented with D-glucose
4500 mg/l, 4 mM L-glutamine and 110 mg/l sodium pyruvate, 10% fetal bovine
serum, 1x penicillin–streptomycin (Pen-Strep) and non-essential amino acids (all
purchased from Gibco-Invitrogen, Waltham, MA, USA). Colon cancer cell line
HT-29, HT115, and SW620 were treated with 5 μM DZNep small-molecule inhibitor
of EZH2 (Sigma, St. Louis, MO, USA). Pharmacological inhibition of Wnt pathway
was conducted using XAV939 (0.25 and 1 μM) and IWP-2 (1 and 5 μM). Inhibition of
TGF-β pathway was conducted as we previously described using 10 μM SB-431542
(Sigma, St. Louis, MO, USA).34 Assays were carried out with appropriate controls
such as dimethyl sulfoxide. Briefly, 10 000 cells were cultured in a 96-well plate and
cell viability was measured at the indicated time points using the alamarBlue
(BUF012B; AbD Serotec, Kidlington, UK) assay.
Transfection. The pre-miR-negative control, hsa-miR-26a-5p, hsa-let-7b-5p,
siControl, and siEZH2 were purchased from Applied Biosystems (Invitrogen,
Carlsbad, CA, USA). Transfection was performed using reverse transfection
approach as described before.14 Briefly, 30 nM (final) pre-miRs or 30 nM (final)
siRNA was diluted in 50 μl of Opti-MEM (11058-021; Gibco, Carlsbad, CA, USA),
whereas 1 μl of Lipofectamine 2000 (Part No: 52758; Invitrogen) were diluted in
50 μl OPTI-MEM. The diluted pre-miR, siRNA, and Lipofectamine 2000 were mixed
and incubated at ambient temperature for 20 min. Twenty microliters of transfection
mixture was added to the plate and subsequently 10 000 cells in transfection
medium (routine culture medium without antibiotics) were added to each well in
60 μl volume. Every experiment was performed in 10 replicates in 96-well cell
culture plates with the appropriate controls. The experiment was repeated at least
two times. Plates were incubated for the indicated time points, and proliferation or
growth inhibition was assessed using the alamarBlue (BUF012B; AbD
Serotec) assay.
Histone methylation quantification (global H3K27 methylation
assay). Colon cancer cell lines HT-29 and SW620 were treated with 5 μM DZNep
small-molecule inhibitor (cat. no. 13828; Cayman Chemical, Ann Arbor, MI, USA) for
5 days. Histones were extracted and quantified (Colorimetric) from control and drug-
treated cells using the EpiQuik Global Histone H3-K27 Assay Kit (P-3020;
Epigentek, Farmingdale, NY, USA) according to the manufacturer's Instructions.
Data were normalized on total histone H3 quantified using the EpiQuik Total Histone
H3 (Methylated H3-K27 Control) Quantification Kit (Colorimetric, Epigentek).
EZH2 quantification by ELISA. Colon cancer cell lines HT-29 and SW620
were treated with 5 μM DZNep drug (13828; Cayman Chemical, Ann Arbor, MI,
USA) for 5 days. In vitro quantitative measurement of EZH2 was executed by
sandwich enzyme immune assay (EZH2, ELISA (enzyme-linked immunosorbent
assay) Kit; MyBioSource Inc., San Diego, CA, USA). Both controls and drug-treated
cells were lysed and analyzed with respective standards according to the
manufacturer's instructions.
Immunoblotting. HT115 cells were transfected with the indicated pre-miR.
Forty-eight hours later, cells were lysed using RIPA buffer (Norgen-Biotek Corp.)
containing 1 × Halt Protease Inhibitor Cocktail (Pierce Inc., Rockford, IL, USA).
Thirty micrograms of total protein were run and blotted using the Bio-Rad V3
Western work flow system according to the manufacturer's recommendation.
Immunoblotting was conducted using anti-EZH2 rabbit polyclonal antibody (D2C9,
1 : 1000 dilution; Cell Signaling, Beverly, MA, USA) overnight at 4 °C. Horseradish
peroxidase (HRP)-conjugated goat anti-rabbit (cat. no. 7074, 1 : 3000 dilution; Cell
Signaling) was used as the secondary antibody, whereas HRP-conjugated anti-
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibody (ab9482, 1 : 10000;
Abcam, Cambridge, MA, USA) was used as the loading control.
Statistical analysis. Statistical analyses and graphing were performed using
Microsoft excel 2010 and GraphPad Prism 6.0 software (GraphPad, San Diego, CA,
USA). P-values were calculated using the two-tailed t-test. Pearson's correlation
was used to assess the correlation between EZH2, hsa-miR-26a, and hsa-let-7b-5p
expression using the GraphPad Prism software.
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